RPG Life Sciences posts Q4 FY24 PAT at Rs. 13.24 Cr
The company has posted net profit of Rs.87.66 crores for the Financial Year ended March 31, 2024
The company has posted net profit of Rs.87.66 crores for the Financial Year ended March 31, 2024
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
GAAP net loss of $1.2 billion and GAAP diluted EPS of $(3.07)
Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
First-quarter 2024 revenues totaled $14.9 billion, a decrease of $3.6 billion, or 20%, compared to the prior-year quarter
2024 full-year revenue guidance raised by US$ 2 billion
Colchicine Capsules are indicated for prophylaxis of gout flares in adult
The USFDA has issued 5 observations pursuant to the completion of audit
Subscribe To Our Newsletter & Stay Updated